The estimated Net Worth of Harrison M Jr Bains is at least $377 Tausend dollars as of 15 July 2022. Mr. Bains owns over 7,200 units of Cara Therapeutics Inc stock worth over $7,272 and over the last 10 years he sold CARA stock worth over $65,160. In addition, he makes $304,524 as Independent Director at Cara Therapeutics Inc.
Sign up
Mr. Bains CARA stock SEC Form 4 insiders trading
Harrison has made over 1 trades of the Cara Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 7,200 units of CARA stock worth $65,160 on 15 July 2022.
The largest trade he's ever made was selling 7,200 units of Cara Therapeutics Inc stock on 15 July 2022 worth over $65,160. On average, Harrison trades about 600 units every 0 days since 2014. As of 15 July 2022 he still owns at least 25,076 units of Cara Therapeutics Inc stock.
You can see the complete history of Mr. Bains stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Harrison Bains biography
Harrison M. Bains Jr. serves as Independent Director of the Company. Mr. Bains served in multiple roles at Bristol Myers Squibb Company, including Vice President, Treasurer and acting Chief Financial Officer from 1988 through his retirement in 2004. Mr. Bains’s career also includes serving as Senior Vice President of the Primary Industries group at Chase Manhattan Bank and 11 years with RJR Nabisco and two of its predecessor companies as Senior Vice President and Treasurer. He currently serves as a director and chair of the Audit Committee of the Mercer Funds, Inc., a registered investment company. He has served as a member of the board of trustees of the Park Avenue Armory since October 2007 and the Civil War Trust since September 2007, and previously served as a member of the board of trustees of the University of Redlands from October 1989 to May 2013, as a member of the board of directors of BG Medicine, Inc. from 2007 to 2015, and as a member of the board of directors of Bank of America Funds from 2010 to 2016. Mr. Bains earned an M.B.A from the University of California, Berkeley and a B.A. in economics from the University of Redlands. He also completed the Advanced Management Program at Harvard Business School. His extensive experience in the biotechnology industry provides him with the qualifications to serve on the Board.
What is the salary of Harrison Bains?
As the Independent Director of Cara Therapeutics Inc, the total compensation of Harrison Bains at Cara Therapeutics Inc is $304,524. There are 10 executives at Cara Therapeutics Inc getting paid more, with Joana Goncalves having the highest compensation of $3,736,190.
How old is Harrison Bains?
Harrison Bains is 76, he's been the Independent Director of Cara Therapeutics Inc since 2014. There are no older and 18 younger executives at Cara Therapeutics Inc.
What's Harrison Bains's mailing address?
Harrison's mailing address filed with the SEC is 9th, 107 Elm St, Stamford, CT 06902, USA.
Insiders trading at Cara Therapeutics Inc
Over the last 11 years, insiders at Cara Therapeutics Inc have traded over $25,200,591 worth of Cara Therapeutics Inc stock and bought 1,874,453 units worth $19,406,983 . The most active insiders traders include Edward Hurwitz, Martin Vogelbaum und Ventures Vi Lprmv Vi, L.L.C.... On average, Cara Therapeutics Inc executives and independent directors trade stock every 19 days with the average trade being worth of $5,343. The most recent stock trade was executed by Christopher Posner on 1 August 2024, trading 4,149 units of CARA stock currently worth $1,452.
What does Cara Therapeutics Inc do?
cara therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat pain, inflammation and pruritus. cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. cara's most advanced patented compound, cr845, is currently undergoing clinical testing for acute pain and uremic pruritus. this compound possesses analgesic, anti-inflammatory and antipruritic activities appropriate for multiple therapeutic applications. in addition, cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.
What does Cara Therapeutics Inc's logo look like?
Complete history of Mr. Bains stock trades at Cara Therapeutics Inc
Cara Therapeutics Inc executives and stock owners
Cara Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Joana Goncalves,
Chief Medical Officer -
Derek Chalmers,
President, Chief Executive Officer, Director -
Frederique Menzaghi,
Senior Vice President, Research and Development, Chief Scientific Officer -
Scott Terrillion,
Chief Compliance Officer, General Counsel, Secretary -
Dr. Derek T. Chalmers D.Sc., Ph.D.,
Co-Founder & Sr. Advisor -
Dr. Frédérique Menzaghi,
Chief Scientific Officer and Sr. VP of R&D -
Dr. Joana Goncalves,
Chief Medical Officer -
Scott M. Terrillion,
Chief Compliance Officer, Gen. Counsel & Corp. Sec. -
Richard Makara,
VP, Head of Accounting, Controller & Principal Accounting Officer -
Martin Vogelbaum,
Lead Independent Director -
Harrison Bains,
Independent Director -
Christopher Posner,
Independent Director -
Jeffrey Ives,
Independent Director -
Thomas Charles Reilly,
Chief Financial Officer -
Christopher A. Posner,
Pres, CEO & Director -
Susan Shiff,
Director -
Richard Makara,
Vice President, Head of Accounting & Controller -
Thomas Reilly,
Chief Financial Officer -
Eric Vandal,
Sr. VP of Commercial -
Dr. Michael E. Lewis Ph.D.,
Co-Founder & Chief Scientific Advisor -
Ventures Vi Lprmv Vi, L.L.C...,
-
Josef Schoell,
Chief Financial Officer -
Dean Slagel,
Director -
Ventures Vi Lprmv Vi, L.L.C...,
-
Michael E Lewis,
Chief Scientific Advisor -
Joseph William Stauffer,
Chief Medical Officer -
Robert Medve,
Chief Medical Officer -
Ventures Vi Lp Rho Capital ...,
-
Charles Ph.D. Moller,
Director -
Biopharma Partners Iii Lpal...,
-
Edward Hurwitz,
Director -
Ryan D Maynard,
CHIEF FINANCIAL OFFICER -
Moltke Lisa Von,
-
Helen M Boudreau,